THE IMPORTANCE OF MYOCARDIAL NECROSIS MARKERS IN THE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
DOI:
https://doi.org/10.47820/recima21.v4i8.3835Keywords:
Acute Myocardial Infarction (AMI) is a commonAbstract
Acute Myocardial Infarction (AMI) is a common and potentially fatal medical emergency, representing one of the main causes of morbidity and mortality globally. Myocardial necrosis markers, such as cardiac troponin and creatine kinase-MB (CK-MB), play a crucial role in the diagnosis and risk stratification of AMI. Objective: The objective of this bibliographic review is to analyze the importance of these markers in the early and accurate diagnosis of AMI. Methodology: Scientific databases in three languages (English, Spanish and Portuguese) were consulted to select 20 relevant articles on the subject, published in the last five years. Results and Discussion: Cardiac troponin was identified as the "gold standard" for the diagnosis of AMI due to its high sensitivity and specificity. Its serial measurement is essential to identify high-risk patients, and CK-MB can be useful as a complementary marker in specific cases. Risk stratification and prognosis based on myocardial necrosis markers are crucial for the identification of patients with worse clinical evolution and the adoption of more intensive therapeutic approaches. Research on new biomarkers, such as myoglobin and BNP, offer promising perspectives to improve diagnosis and risk stratification in AMI. Conclusion: Myocardial necrosis markers are essential for an early and accurate diagnosis of AMI, providing better patient care and reducing morbidity and mortality associated with this highly relevant clinical condition in cardiology.
Downloads
References
Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-2064. doi: 10.1056/NEJMra1606915.
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, & Cannon CP. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. New England Journal of Medicine, 335(18), 1342-1349.
Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54-61. doi: 10.1373/clinchem.2011.165795.
Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, ... & Sabatine MS. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2° P–TIMI 50 trial. Journal of the American College of Cardiology, 66(21), 2314-2321.
Collinson PO. High-sensitivity cardiac troponin assays. Clinical Chemistry, 54(7), 1133-1140.
Eggers KM, Oldgren J, Nordenskjöld A, & Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. American Heart Journal, 143(5), 966-972.
Fain J, Mathews M, Ransom T, Smith A, Thomas S, Wu AH, & Apple FS. Pathology Consultation on Cardiac Troponin Testing in Patients With Suspected Acute Coronary Syndrome. American Journal of Clinical Pathology, 143(4), 423-425.
Giannitsis E, Katus HA, & Plebani M. Quality specifications for cardiac troponin assays. Clinical Chemistry and Laboratory Medicine, 48(6), 757-763.
Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054. doi: 10.1093/eurheartj/ehr236.
Holzmann MJ, Jungner P, & Walldius G. Low apolipoprotein B/apolipoprotein A-I ratio predicts myocardial infarction: an updated meta-analysis of 23 prospective studies. American Journal of Cardiology, 109(5), 666-674.
Keller T, Zeller T, Ojeda F, Tzikas S, Lillpopp L, Sinning C, ... & Wild PS. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. Journal of the American Medical Association, 306(24), 2684-2693.
Korff S, Katus HA, & Giannitsis E. Differential diagnosis of elevated troponins. Heart, 98(15), 1121-1127.
Lindahl B, Venge P, & James S. The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. American Heart Journal, 181, 147-154.
Lippi G, & Plebani M. The expanding role of troponins in the management of coronary artery disease. Journal of Medical Biochemistry, 30(3), 165-171.
Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, ... & Pfeffer MA. A sensitive cardiac troponin T assay in stable coronary artery disease. New England Journal of Medicine, 361(26), 2538-2547.
Park KC, Gaze DC, Collinson PO, & Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovascular Research, 90(3), 280-287.
Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-867. doi: 10.1056/NEJMoa0900428.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617.
Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, ... & Mueller C. Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation, 126(11), 1200-1207.
Wu AH, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Llanos J, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2018;64(4):e33-e62. doi: 10.1373/clinchem.2017.281701.
Downloads
Published
How to Cite
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
